pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Aug 28·1 min read
save

Former CDC leaders resign, warn of lingering political interference and call for stronger public health safeguards

Aug 28, 2026·read at STAT ↗RegulatoryNegative

Three former CDC officials-Debra Houry, Daniel Jernigan, and Demetre Daskalakis-announced they resigned from the agency last year. Their careers included senior roles in disease control, emerging infections, and immunization, and they now serve as advisers and consultants to public‑health and pharmaceutical organizations.

They said they left because they could no longer stay silent as political interference threatened scientific integrity at the CDC. The authors argue that the problems they highlighted are not isolated incidents but reflect deeper vulnerabilities in the public‑health system.

The piece calls for more than a return to the agency’s previous state. It urges Congress to enact safeguards that keep public‑health institutions independent of any administration, whether Republican or Democratic, to ensure resilient disease‑control capabilities for the future.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: We quit the CDC last year. The problems we protested remain”

read at STAT ↗
1,447 words · retrieved Aug 28
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTRAZENECA2Sanofi2ViiV Healthcare Company2
drugs
hepatitis B vaccine
topics
Vaccines5Vaccine3Pulmonology2AdComApproval

related stories

  • Sep 14After a brief storm of political headwinds, mRNA is back with strong momentumBioSpace
  • Sep 8Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durabilityFierce Biotech
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • May 29STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and moreSTAT
  • 5d agoSTAT+: AstraZeneca opens new Boston siteSTAT